Difference between revisions of "Lipefilgrastim (Lonquex)"
Jump to navigation
Jump to search
m |
m |
||
| Line 12: | Line 12: | ||
[[Category:Subcutaneous medications]] | [[Category:Subcutaneous medications]] | ||
[[Category:Granulocyte colony-stimulating factors]] | [[Category:Granulocyte colony-stimulating factors]] | ||
| + | [[Category:Recombinant medications]] | ||
| + | |||
[[Category:EMA approved in 2013]] | [[Category:EMA approved in 2013]] | ||
[[Category:Stub]] | [[Category:Stub]] | ||
Latest revision as of 14:34, 28 February 2024
Mechanism of action
From NCI: "A long acting glyco-pegylated recombinant form of human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Similar to G-CSF, lipegfilgrastim binds to and activates specific cell surface receptors, and stimulates neutrophil progenitor proliferation and differentiation."
History of changes in EMA indication
- 2013-07-25: Initial authorization
Also known as
- Code name: XM22
- Brand name: Lonquex